Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

SUPN

Supernus Pharmaceuticals Inc

Last Close
Oct 04 • 04:00PM ET
32.02
Dollar change
-0.08
Percentage change
-0.25 		%
Held by: IJR VTI CALF VB IWM VBR VXF AVUV SPSM IWN Scroll to Statements
IndexRUT P/E362.63 EPS (ttm)0.09 Insider Own4.25% Shs Outstand54.72M Perf Week4.13%
Market Cap1.76B Forward P/E17.56 EPS next Y1.82 Insider Trans-0.59% Shs Float52.76M Perf Month-6.86%
Income5.24M PEG214.57 EPS next Q0.44 Inst Own107.89% Short Float12.88% Perf Quarter22.03%
Sales630.16M P/S2.80 EPS this Y-14.94% Inst Trans4.04% Short Ratio15.32 Perf Half Y-4.56%
Book/sh17.39 P/B1.84 EPS next Y-8.83% ROA0.40% Short Interest6.80M Perf Year18.99%
Cash/sh6.30 P/C5.08 EPS next 5Y1.69% ROE0.56% 52W Range21.99 - 35.44 Perf YTD10.64%
Dividend Est.- P/FCF11.43 EPS past 5Y-59.02% ROI0.53% 52W High-9.65% Beta0.87
Dividend TTM- Quick Ratio1.69 Sales past 5Y9.22% Gross Margin74.86% 52W Low45.61% ATR (14)0.91
Dividend Ex-Date- Current Ratio1.91 EPS Y/Y TTM-88.31% Oper. Margin6.45% RSI (14)50.67 Volatility2.78% 3.01%
Employees652 Debt/Eq0.04 Sales Y/Y TTM-0.61% Profit Margin0.83% Recom2.00 Target Price39.25
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q2451.32% Payout0.00% Rel Volume0.37 Prev Close32.10
Sales Surprise13.10% EPS Surprise94.92% Sales Q/Q24.17% EarningsAug 06 AMC Avg Volume443.64K Price32.02
SMA200.98% SMA50-0.90% SMA2006.84% Trades Volume163,741 Change-0.25%
Date Action Analyst Rating Change Price Target Change
Sep-11-24Downgrade Piper Sandler Overweight → Neutral $41 → $36
Jan-03-23Resumed Jefferies Buy $44 → $45
Dec-01-21Resumed Jefferies Buy $40 → $44
Apr-13-21Upgrade Jefferies Hold → Buy $25 → $40
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Show Previous Ratings
Sep-24-24 07:30AM
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
(GlobeNewswire)
Sep-19-24 04:30PM
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
(GlobeNewswire)
Sep-16-24 10:50AM
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
(Insider Monkey)
Sep-11-24 02:38PM
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
(Benzinga) -7.20%
Aug-28-24 04:15PM
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
(GlobeNewswire)
07:00AM Loading…
Aug-19-24 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Aug-09-24 09:55AM
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
(Zacks)
Aug-06-24 08:00PM
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
(Zacks) +14.49%
06:45PM
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
(Zacks)
05:36PM
Supernus: Q2 Earnings Snapshot
(Associated Press Finance)
04:06PM
Supernus Announces Second Quarter 2024 Financial Results
(GlobeNewswire)
Aug-01-24 04:30PM
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
(GlobeNewswire)
Jul-23-24 04:13PM
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
(GlobeNewswire)
Jul-19-24 01:58PM
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
(InvestorPlace)
May-30-24 04:25PM
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
(GlobeNewswire)
11:53AM Loading…
May-24-24 11:53AM
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
(Zacks)
May-23-24 04:05PM
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
(GlobeNewswire)
May-10-24 01:38PM
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
(GuruFocus.com)
May-09-24 04:05PM
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
(GlobeNewswire)
11:56AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:42AM
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 10:56PM
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
(InvestorPlace)
07:00PM
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
(Zacks)
04:05PM
Supernus Announces First Quarter 2024 Financial Results
(GlobeNewswire)
May-07-24 11:46AM
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
(MT Newswires)
10:00AM
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree (Viloxazine XR) in Latin America
(PR Newswire)
09:15AM
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
May-01-24 08:00AM
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
(GlobeNewswire)
Apr-24-24 04:05PM
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
(GlobeNewswire)
Apr-08-24 12:11PM
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
(Benzinga) -6.32%
08:00AM Loading…
08:00AM
Supernus Provides Regulatory Update for SPN-830
(GlobeNewswire)
Mar-27-24 04:37PM
Corporate Insiders Are Selling These 10 Small-Cap Stocks
(Insider Monkey)
Mar-06-24 04:30PM
Supernus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Mar-04-24 08:28PM
11 Best Small Cap Pharma Stocks to Invest In
(Insider Monkey)
Feb-28-24 04:30PM
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
(GlobeNewswire)
09:19AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
(Insider Monkey)
07:17AM
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
Feb-27-24 07:30PM
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
(Zacks)
06:50PM
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
(Zacks)
06:02PM
Supernus: Q4 Earnings Snapshot
(Associated Press Finance)
05:00PM
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
(GuruFocus.com)
04:05PM
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Feb-26-24 09:15AM
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
Feb-20-24 10:00AM
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Feb-13-24 04:05PM
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
(GlobeNewswire)
Feb-05-24 08:30AM
Supernus Wins Infringement and Validity Case on Trokendi XR against Torrent
(GlobeNewswire)
Dec-19-23 07:30AM
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada
(GlobeNewswire)
Dec-14-23 07:43PM
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
(InvestorPlace)
Nov-18-23 05:03AM
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...
(GuruFocus.com)
Nov-10-23 12:10PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-09-23 09:54AM
Q3 2023 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents) +11.14%
Nov-08-23 07:30PM
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
(Zacks)
07:15PM
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
06:08PM
Supernus: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Third Quarter 2023 Financial Results
(GlobeNewswire)
Nov-07-23 04:30PM
Supernus to Participate in the Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-02-23 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Nov-01-23 10:01AM
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
(Zacks)
Oct-25-23 04:15PM
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
(GlobeNewswire)
Oct-16-23 05:34PM
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
(GlobeNewswire)
Oct-09-23 04:45PM
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
(GlobeNewswire)
Sep-27-23 04:15PM
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
(GlobeNewswire)
Sep-26-23 07:37PM
Supernus Pharmaceuticals (SUPN): A Hidden Gem in the Market? A Comprehensive Analysis of Its ...
(GuruFocus.com)
Sep-09-23 08:00PM
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
(GlobeNewswire)
Aug-31-23 05:30PM
Supernus to Participate in the Wells Fargo Healthcare Conference
(GlobeNewswire)
Aug-21-23 09:00AM
Bethany L. Sensenig Joins Supernus Board of Directors
(GlobeNewswire)
Aug-08-23 08:30PM
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
(Zacks) -7.23%
07:55PM
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:40PM
Supernus: Q2 Earnings Snapshot
(AP Finance)
04:17PM
Supernus Announces Second Quarter 2023 Financial Results
(GlobeNewswire)
Jul-28-23 02:56PM
10 Best Small Cap Pharma Stocks to Buy
(Insider Monkey)
Jul-25-23 06:36AM
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?
(Simply Wall St.)
Jul-24-23 04:05PM
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
(GlobeNewswire)
Jun-27-23 11:50AM
The five-year shareholder returns and company earnings persist lower as Supernus Pharmaceuticals (NASDAQ:SUPN) stock falls a further 9.4% in past week
(Simply Wall St.)
Jun-21-23 08:00PM
SUPN: What does Argus have to say about SUPN?
(Argus Research)
Jun-10-23 07:40AM
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
(Motley Fool)
May-31-23 04:15PM
Supernus to Participate in the Jefferies Healthcare Conference
(GlobeNewswire)
May-11-23 08:39AM
Top Healthcare Stocks for May 2023
(Investopedia)
May-10-23 11:23AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2023 Earnings Call Transcript
(Insider Monkey)
May-09-23 08:30PM
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
(Zacks)
07:05PM
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
(Zacks)
06:09PM
Supernus: Q1 Earnings Snapshot
(AP Finance)
04:05PM
Supernus Announces First Quarter 2023 Financial Results
(GlobeNewswire)
May-02-23 04:05PM
Supernus to Present at the Bank of America 2023 Health Care Conference
(GlobeNewswire)
Apr-26-23 08:00PM
SUPN: What does Argus have to say about SUPN?
(Argus Research)
Apr-25-23 04:15PM
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
(GlobeNewswire)
Apr-03-23 04:05PM
Supernus Announces Repayment of Convertible Notes
(GlobeNewswire)
Mar-31-23 12:41PM
Top Small-Cap Stocks for April 2023
(Investopedia)
Mar-30-23 05:22PM
Top Healthcare Stocks for April 2023
(Investopedia)
Mar-08-23 04:05PM
Supernus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Mar-02-23 08:29PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-01-23 04:55PM
Supernus to Present at the Cowen 43rd Annual Health Care Conference
(GlobeNewswire)
05:50AM
Q4 2022 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
Feb-28-23 05:25PM
Supernus Pharmaceuticals (SUPN) Q4 Earnings and Revenues Lag Estimates
(Zacks)
04:05PM
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Feb-21-23 10:00AM
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?
(Zacks)
Feb-14-23 04:30PM
Supernus Enters Into $150 Million Credit Facility
(GlobeNewswire)
09:27AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
(Simply Wall St.)
Feb-09-23 06:15PM
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
(GlobeNewswire)
Jan-18-23 08:11AM
Supernus Pharmaceuticals (NASDAQ:SUPN) investors are up 3.6% in the past week, but earnings have declined over the last three years
(Simply Wall St.)
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GEMAYEL GEORGESDirectorSep 13 '24Option Exercise11.4610,000114,60023,315Sep 17 04:10 PM
GEMAYEL GEORGESDirectorSep 13 '24Sale31.3313,886435,04813,315Sep 17 04:10 PM
GEORGES GEMAYELDirectorSep 13 '24Proposed Sale31.3313,886435,041Sep 13 04:30 PM
Khattar Jack A.President, CEOSep 03 '24Option Exercise0.0021,0000936,217Sep 03 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOAug 20 '24Option Exercise0.001,250010,251Aug 20 05:00 PM
TAMI TILLOTSON MARTINFormer OfficerAug 02 '24Proposed Sale29.024,000116,074Aug 02 04:16 PM
TAMI TILLOTSON MARTINFormer OfficerAug 01 '24Proposed Sale29.313,10090,856Aug 01 04:19 PM
TAMI TILLOTSON MARTINFormer OfficerJul 31 '24Proposed Sale30.135,000150,650Jul 31 04:41 PM
TAMI TILLOTSON MARTINFormer OfficerJul 30 '24Proposed Sale30.562,90088,610Jul 30 04:02 PM
TAMI TILLOTSON MARTINFormer OfficerJul 29 '24Proposed Sale30.755,000153,750Jul 29 04:08 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 21 '24Option Exercise25.3014,491366,62223,061Mar 25 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 21 '24Sale35.3114,491511,6778,570Mar 25 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 20 '24Option Exercise25.3040010,1208,970Mar 22 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 20 '24Sale35.3140014,1248,570Mar 22 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 19 '24Option Exercise25.3012,364312,80920,934Mar 21 05:01 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 19 '24Sale35.3112,364436,5738,570Mar 21 05:01 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 13 '24Option Exercise17.6162,3661,098,52344,686Mar 15 06:39 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 13 '24Sale33.7462,3662,104,2898,570Mar 15 06:39 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 12 '24Option Exercise12.983,88450,41412,454Mar 14 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 12 '24Sale32.993,884128,1338,570Mar 14 05:00 PM
Mottola FrankSVP, Quality, GMP, Ops, ITFeb 28 '24Option Exercise0.0099008,239Feb 29 05:01 PM
Khattar Jack A.President, CEOFeb 28 '24Option Exercise0.0035,0000932,005Feb 29 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 26 '24Option Exercise9.135,00045,65013,570Feb 28 05:01 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 26 '24Sale30.215,000151,0508,570Feb 28 05:01 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsJan 10 '24Option Exercise9.248,00073,92093,664Jan 12 05:00 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsJan 10 '24Sale27.918,000223,28085,664Jan 12 05:00 PM
Rubin JonathanSr. VP, Chief Medical OfficerDec 22 '23Option Exercise0.0060003,447Dec 26 05:01 PM
Khattar Jack A.President, CEODec 22 '23Option Exercise0.0025,0000892,463Dec 26 05:00 PM
NEWHALL CHARLES W IIIDirectorNov 16 '23Option Exercise9.247,45768,903119,589Nov 20 05:00 PM
NEWHALL CHARLES W IIIDirectorNov 16 '23Sale28.012,50070,025117,089Nov 20 05:00 PM
Hudson Frederick M.DirectorNov 15 '23Option Exercise9.247,45768,90342,324Nov 17 05:00 PM
Hudson Frederick M.DirectorNov 15 '23Sale28.509,093259,15033,231Nov 17 05:00 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 14 '23Option Exercise9.242,00018,4806,791Nov 16 05:00 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 14 '23Sale28.131,11031,2245,681Nov 16 05:00 PM
DEC TIMOTHY CSenior Vice-President & CFOOct 13 '23Option Exercise0.004,00007,000Oct 13 05:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.